BMS-247550 Bristol-Myers Squibb/GBF.
Bristol-Myers Squibb and the German Research Centre for Biotechnology are developing BMS-247550 as one of a series of epothilones, for the potential treatment of various forms of cancer. BMS-247550 had successfully completed phase I trials by September 2000 and by February 2001, phase II trials had been initiated for a variety of tumor types in collaboration with the National Cancer Institute; at this time, DNA filing was expected in 2003, and commercialization in 2004. By April 2002, phase I trials in children had also been initiated. As of May 2002, phase II studies had been conducted in patients with non-small-cell lung cancer and breast cancer.
Lin
Nancy
N
Division of Hematology and Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Brakora
Katherine
K
Seiden
Michael
M
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D034261:Epothilones / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D013678:Technology, Pharmaceutical / Q000379:methods*
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D034261:Epothilones; C430592:ixabepilone